Prot #BAY 1163877/16443: An Open Label, Non-Randomized, Phase I Dose Escalation Study To Characterize Safety, Tolerability, Pharmacokinetics And Maximum Tolerated Dose of BAY 1163877 in Subjects With Refractory, Locally Advanced Or Metastatic Solid Tumors

Project: Research project

Project Details

StatusFinished
Effective start/end date6/21/17 → 8/31/22

Funding

  • Bayer HealthCare Pharmaceuticals, Inc. (Prot #BAY 1163877/16443)